Brought to you by 
CANbridge gains its second cancer project through deal with EUSA
Jul 2015
Executive Summary
CANbridge Life Sciences Ltd. gained its second cancer project, licensing exclusive rights to sell in China EUSA Pharma's Caphosol oral rinse.
Deal Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CANbridge gains its second cancer project through deal with EUSA
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice